Citations

Clear

2303 citation(s) found for "Yu, Edward".

Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
Li, Dalin , Debbas, Philip , McGovern, Dermot , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Hampton, Melissa, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Chiorean, Michael , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Lum, Donald , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Damas, Oriana M. , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Cheng, Susan , Group, CORALE-IBD Study, Botwin, Gregory J., Mengesha, Emebet , White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C. , McGovern, Dermot P.B.

Mayo Clinic

Inflammatory Bowel Diseases | August 23, 2022 | Volume: 29 | Issue: 6 | Pages: 883-887

10.1093/ibd/izac174 | PMID 35998072 Get It

AbstractBackgroundThe safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.MethodsWe compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD.ResultsThe study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse.ConclusionThe frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.
Common Variants Near ZIC1 and ZIC4 in Autopsy‐Confirmed Multiple System Atrophy
Hopfner, Franziska , Tietz, Anja, Ruf, Viktoria , Ross, Owen A. , Koga, Shunsuke , Attems, Johannes , Beach, Thomas, Beller, Allison , Duyckaerts, Charles, Evsyukov, Valentin, Flanagan, Margaret E. , Frosch, Matthew P. , Gearing, Marla , Gelpí, Ellen , Gerpen, Jay A. van, Glass, Jonathan D. , Grinberg, Lea T. , Halliday, Glenda M. , Höllerhage, Matthias , Huitinga, Inge , Keene, Dirk, Kovács, Gábor G. , Lee, Edward B. , Xiong, Chengjie , Martı́, Marı́a José , Mackenzie, Ian R. , Mollenhauer, Brit , Neumann, Manuela , Newell, Kathy L. , Pendziwiat, Manuela , Molina‐Porcel, Laura , Rábano, Alberto , Rajput, Alex, Rajput, Ali H. , Reimann, Regina , Selvackadunco, Sashika , Simuni, Tanya , Svenningsson, Per , Trenkwalder, Claudia , Troakes, Claire , Trojanowski, John Q. , Uitti, Ryan J. , Xie, Tao , Ximelis, Teresa , Yebenes, Justo, Müller, Ulrich , Schellenberg, Gerard D., Herms, Jochen , Kuhlenbäumer, Gregor , Deuschl, Günther , Gelpi, Ellen , Van Gerpen, Jay A, Halliday, Glenda , Irwin, David J , Mollenhauer, Brit , Pantelyat, Alex , Svenningsson, Per , Höglinger, Günter U , Koga, Shunsuke , Ross, Owen A , Kovacs, Gabor G , Xiong, Chengjie , Grinberg, Lea , Molina-Porcel, Laura , Troakes, Claire , Hopfner, Franziska , Lee, Edward B , Simuni, Tanya , Dickson, Dennis W. , Aguzzi, Adriano , Cheshire, William P. , Deerlin, Vivianna M. Van , Desplats, Paula , Deuschl, Günther , Duyckaerts, Charles , Ellinghaus, David , Franke, André , Ghetti, Bernardino , Helbig, Ingo , Irwin, David J. , McKeith, Ian G. , McLean, Catriona , Pantelyat, Alexander , Peters, Annette , Matěj, Radoslav , Scott, William K. , Seeley, William W. , Stadelmann, Christine , Thomas, Alan , White, Charles L. , Wszołek, Zbigniew K. , Schellenberg, Gerard D., Höglinger, Günter U. , Flanagan, Margaret E

Mayo Clinic

Movement Disorders | August 23, 2022 | Volume: 37 | Issue: 10 | Pages: 2110-2121

10.1002/mds.29164 | PMID 35997131 Get It

ABSTRACT Background Multiple System Atrophy is a rare neurodegenerative disease with alpha‐synuclein aggregation in glial cytoplasmic inclusions and either predominant olivopontocerebellar atrophy or striatonigral degeneration, leading to dysautonomia, parkinsonism, and cerebellar ataxia. One prior genome‐wide association study in mainly clinically diagnosed patients with Multiple System Atrophy failed to identify genetic variants predisposing for the disease. Objective Since the clinical diagnosis of Multiple System Atrophy yields a high rate of misdiagnosis when compared to the neuropathological gold standard, we studied only autopsy‐confirmed cases. Methods We studied common genetic variations in Multiple System Atrophy cases (N = 731) and controls (N = 2898). Results The most strongly disease‐associated markers were rs16859966 on chromosome 3, rs7013955 on chromosome 8, and rs116607983 on chromosome 4 with P ‐values below 5 × 10 −6 , all of which were supported by at least one additional genotyped and several imputed single nucleotide polymorphisms. The genes closest to the chromosome 3 locus are ZIC1 and ZIC4 encoding the zinc finger proteins of cerebellum 1 and 4 (ZIC1 and ZIC4). Interpretation Since mutations of ZIC1 and ZIC4 and paraneoplastic autoantibodies directed against ZIC4 are associated with severe cerebellar dysfunction, we conducted immunohistochemical analyses in brain tissue of the frontal cortex and the cerebellum from 24 Multiple System Atrophy patients. Strong immunohistochemical expression of ZIC4 was detected in a subset of neurons of the dentate nucleus in all healthy controls and in patients with striatonigral degeneration, whereas ZIC4‐immunoreactive neurons were significantly reduced inpatients with olivopontocerebellar atrophy. These findings point to a potential ZIC4‐mediated vulnerability of neurons in Multiple System Atrophy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
A Cohort Study of the Age at Menopause in Female Patients With and Without Inflammatory Bowel Disease
Moktan, Varun , Daoud, Nader , Tremaine, William J., Kane, Sunanda V. , Hochwald, Alexander , Hodge, David O. , Farraye, Francis A. , Kane, S , Hochwald, Alexander P, Farraye, Francis A , Loftus, Edward V. , Hashash, Jana G. , Faubion, Stephanie S.

Mayo Clinic

Crohn's & Colitis 360 | August 4, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/crocol/otac027 | PMID 36045902 Get It

Abstract Background Menopause, defined by the complete cessation of menstrual cycles for 12 consecutive months, may occur at a younger age in women who have concomitant immune dysregulation. Our aim was to determine whether women with inflammatory bowel disease (IBD) experience an earlier onset of menopause compared to women without IBD. Methods This was a retrospective cohort study using resources of the Rochester Epidemiology Project, a collaboration between clinics, hospitals, and medical facilities in Olmsted County, Minnesota. From these people, women who were diagnosed with IBD between 1970 and 2010 comprised the case cohort while the reference cohort included women with no diagnosis of IBD. Data including age, body mass index (BMI), ethnicity, smoking status, age at onset of menopause, and current use of hormone therapy were collected. Patients with history of hysterectomy or oophorectomy were excluded. Wilcoxon rank-sum test for numeric variables and Fisher’s exact test for categorical variables were used to analyze the data. Results A total of 171 women met criteria for inclusion (83 cases and 88 controls). Mean age of menopause in women with IBD was 50.0 years compared to 51.5 years in women with no IBD (P = .006). There was no difference in BMI of women with and without IBD (28.7 versus 28.2 kg m−2; P = .9), respectively. There were more former smokers (33.7%) and current (6%) smokers in the IBD group (P = .009) compared to the non-IBD group. Conclusions IBD is associated with an earlier onset of menopause. Although it is unclear if this mean difference of 1.5 years is clinically relevant, it is known that early menopause is associated with an increased risk of osteoporosis and cardiovascular disease. Further research on the possible mechanisms is needed.
Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey
Yoshida, Akira , Kim, Minchul , Kuwana, Masataka , Ravichandran, Naveen , Makol, Ashima , Sen, Parikshit , Agarwal, Vishwesh , Kardeş, Sinan , Day, Jessica , Milchert, Marcin , Joshi, Mrudula , Salim, Babur , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Parodis, Ioannis , Selva-O’Callaghan, Albert , Nikiphorou, Elena , Chatterjee, Tulika , Tan, Ai Lyn , Nune, Arvind , Ziadé, Nelly , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manesh, Manoj M, Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Pandey, Arun Kumar R, Pauling, John D , Sambataro, Gianluca , Atzeni, Fabiola , Govoni, Marcello, Bocci, Elena Bartoloni, Orsolini, Giovanni , Danielli, Maria Giovanna, Tehozol, Erick Adrian Zamora , Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos , Aharonov, Or, Maurier, F. , Meyer, Alain, Nagy‐Vincze, Melinda , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie , Landon‐Cardinal, Océane , Shaharir, Syahrul Sazliyana , Zuleta, Wilmer Gerardo Rojas, Silva, José António Pereira, Gupta, Latika , Lilleker, James B , Day, Jessica , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Selva O'Callaghan, Albert , Tan, Ai Lyn , Nune, Arvind , Ziade, Nelly , Knitza, Johannes , Distler, Oliver , Chinoy, Hector , Gupta, Latika , Milchert, Marcin , Agarwal, Vikas , Joshi, Mrudula , Agarwal, Vishwesh , Kim, Minchul , Makol, Ashima , Velikova, Tsvetelina , Chatterjee, Tulika , Pauling, John D , Naveen, R , Zamora Tehozol, Erick Adrian , Sen, Parikshit , Yoshida, Akira , Singh, Yogesh Preet , Gheita, Tamer A. , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Barman, Bhupen , Ranjan, Rajiv , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Chandwar, Kunal , Cansu, Döndü Üsküdar , Wincup, Chris , Papa, Nicoletta Del , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Angelis, Rossella De , Venerito, Vincenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Gil‐Vila, Albert , Gonzalez, Raquel Aranega, Kimura, Naoki, Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Hoff, Leonardo Santos , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena

Mayo Clinic

Rheumatology | August 3, 2022 | Volume: 62 | Issue: 3 | Pages: 1204-1215

10.1093/rheumatology/keac441 | PMID 35920795 Get It

AbstractObjectivesThe assessment of physical function is fundamental in the management of patients with idiopathic inflammatory myopathies (IIMs). We aimed to investigate the physical function of patients with IIMs compared with those with non-IIM autoimmune rheumatic diseases (AIRDs) utilizing Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function (PF) data obtained in the COVAD study, an international self-reported e-survey assessing the safety of COVID-19 vaccines in AIRDs.MethodsDemographics, AIRD diagnosis, disease activity, and PROMIS PF short form-10a data were extracted from the COVAD database. PROMIS PF-10a scores were compared between disease categories and stratified by disease activity. Factors affecting PROMIS PF-10a scores other than disease activity were identified by multivariable regression analysis in patients with inactive disease.ResultsA total of 1057 IIM patients, 3635 non-IIM AIRD patients and 3981 healthy controls (HCs) responded to the COVAD e-survey from April to August 2021. Using a binomial regression model, the predicted mean of PROMIS PF-10a scores was significantly lower in IIM patients compared with non-IIM AIRD patients or HCs [36.3 (95% CI 35.5, 37.1) vs 41.3 (95% CI 40.2, 42.5) vs 46.2 (95% CI 45.8, 46.6), P < 0.001], irrespective of disease activity. The independent factors for lower PROMIS PF-10a scores in patients with inactive disease were older age, female, longer disease duration, and a diagnosis of inclusion body myositis or polymyositis.ConclusionPhysical function is significantly impaired in IIMs compared with non-IIM AIRDs or HCs, even in patients with inactive disease. Our study highlights a critical need for better strategies to minimize functional disability in patients with IIMs.
Seeking Standardized Definitions for HLA-incompatible Kidney Transplants: A Systematic Review
Jatana, Sukhdeep , Zhao, Hedi , Bow, Laurine M., Horak, Tillie, Amar‐Zifkin, Alexandre , Dadhania, Darshana M. , Cooper, Matthew , Kraus, Edward S., Sapir‐Pichhadze, Ruth , Group, on behalf of the Banff Antibody-Mediated Injury Working, Cooper, Matthew , Cozzi, Emanuele , Batal, Ibrahim , Horak, Tillie E., Schinstock, Carrie A. , Askar, Medhat , Naesens, Maarten , Group, on behalf of the Banff Antibody-Mediated Injury Working

Mayo Clinic

Transplantation | August 2, 2022 | Volume: 107 | Issue: 1 | Pages: 231-253

10.1097/tp.0000000000004262 | PMID 35915547 Get It

Background. There is no standard definition for “HLA incompatible” transplants. For the first time, we systematically assessed how HLA incompatibility was defined in contemporary peer-reviewed publications and its prognostic implication to transplant outcomes. Methods. We combined 2 independent searches of MEDLINE, EMBASE, and the Cochrane Library from 2015 to 2019. Content-expert reviewers screened for original research on outcomes of HLA-incompatible transplants (defined as allele or molecular mismatch and solid-phase or cell-based assays). We ascertained the completeness of reporting on a predefined set of variables assessing HLA incompatibility, therapies, and outcomes. Given significant heterogeneity, we conducted narrative synthesis and assessed risk of bias in studies examining the association between death-censored graft failure and HLA incompatibility. Results. Of 6656 screened articles, 163 evaluated transplant outcomes by HLA incompatibility. Most articles reported on cytotoxic/flow T-cell crossmatches (n = 98). Molecular genotypes were reported for selected loci at the allele-group level. Sixteen articles reported on epitope compatibility. Pretransplant donor-specific HLA antibodies were often considered (n = 143); yet there was heterogeneity in sample handling, assay procedure, and incomplete reporting on donor-specific HLA antibodies assignment. Induction (n = 129) and maintenance immunosuppression (n = 140) were frequently mentioned but less so rejection treatment (n = 72) and desensitization (n = 70). Studies assessing death-censored graft failure risk by HLA incompatibility were vulnerable to bias in the participant, predictor, and analysis domains. Conclusions. Optimization of transplant outcomes and personalized care depends on accurate HLA compatibility assessment. Reporting on a standard set of variables will help assess generalizability of research, allow knowledge synthesis, and facilitate international collaboration in clinical trials.
Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry
Barnes, Edward L. , Deepak, Parakkal , Beniwal‐Patel, Poonam , Raffals, Laura H., Kayal, Maia , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I, Galanko, Joseph A. , Jiang, Yue , Long, Millie D. , Dubinsky, Marla , Herfarth, Hans H , Kayal, Maia , Deepak, Parakkal , Jiang, Yue , Barnes, Edward L , Chang, Shannon, Cross, Raymond K. , Herfarth, Hans

Mayo Clinic

Crohn's & Colitis 360 | August 2, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/crocol/otac030 | PMID 36082341 Get It

Abstract Background Much of our understanding about the natural history of pouch-related disorders has been generated from selected populations. We designed a geographically diverse, prospective registry to study the disease course among patients with 1 of 4 inflammatory conditions of the pouch. The primary objectives in this study were to demonstrate the feasibility of a prospective pouch registry and to evaluate the predominant treatment patterns for pouch-related disorders. Methods We used standardized diagnostic criteria to prospectively enroll patients with acute pouchitis, chronic antibiotic-dependent pouchitis (CADP), chronic antibiotic refractory pouchitis (CARP), or Crohn’s disease (CD) of the pouch. We obtained detailed clinical and demographic data at the time of enrollment, along with patient-reported outcome (PRO) measures. Results We enrolled 318 patients (10% acute pouchitis, 27% CADP, 12% CARP, and 51% CD of the pouch). Among all patients, 55% were on a biologic or small molecule therapy. Patients with CD of the pouch were more likely to use several classes of therapy (P < .001). Among patients with active disease at the time of enrollment, 23% with CARP and 40% with CD of the pouch were in clinical remission at 6 months after enrollment. Conclusions In a population where most patients had refractory inflammatory conditions of the pouch, we established a framework to evaluate PROs and clinical effectiveness. This infrastructure will be valuable for long-term studies of real-world effectiveness for pouch-related disorders.
Performance measures for colonoscopy in inflammatory bowel disease patients: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative
Dekker, Evelien , Nass, Karlijn J., Iacucci, Marietta , Murino, Alberto , Carretero, Cristina , Cortas, George, Despott, Edward J. , Keuchel, Martin , Monged, Ashraf , Neumann, Helmut , Omar, M. , Rutter, Matthew D. , Bisschops, Raf , Karstensen, John Gásdal , Neumann, Helmut , Pellisé, Maria , Rutter, Matthew D , Bisschops, Raf , Dekker, Evelien , Iacucci, Marietta , Sabino, João , Bugajski, Marek , East, James E. , Kaminski, Michal Filip , Löwenberg, Mark , Nardone, Olga Maria , Omar, Mahmoud M., Peyrin‐Biroulet, Laurent

Mayo Clinic

Endoscopy | August 1, 2022 | Volume: 54 | Issue: 09 | Pages: 904-915

10.1055/a-1874-0946 | PMID 35913069 Get It

AbstractThe European Society of Gastrointestinal Endoscopy (ESGE) presents a short list of performance measures for colonoscopy in inflammatory bowel disease (IBD) patients. Current performance measures for colonoscopy mainly focus on detecting (pre)malignant lesions. However, these performance measures are not relevant for all colonoscopy indications in IBD patients. Therefore, our aim was to provide endoscopy services across Europe and other interested countries with a tool for quality monitoring and improvement in IBD colonoscopy. Eight key performance measures and one minor performance measure were recommended for measurement and evaluation in daily endoscopy practice.
Dietary fat in relation to all‐cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data fromCALGB80405 (Alliance)/SWOG80405
Blarigan, Erin L. Van , Bainter, Tiffany M., Ng, Kimmie , Niedzwiecki, Donna , Giovannucci, Edward L. , Lenz, Heinz‐Josef , Polite, Blasé N. , Höchster, Howard S. , Goldberg, Richard M. , Blanke, Charles D. , Ciombor, Kristen K. , Meyerhardt, Jeffrey A. , Van Blarigan, Erin L , Lenz, Heinz-Josef , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Ma, Chao , Ou, Fang‐Shu , Venook, Alan P. , Mayer, Robert J. , O’Reilly, Eileen M.

Mayo Clinic

International Journal of Cancer | July 29, 2022 | Volume: 152 | Issue: 2 | Pages: 123-136

10.1002/ijc.34230 | PMID 35904874 Get It

AbstractData on diet and survival among people with metastatic colorectal cancer are limited. We examined dietary fat in relation to all‐cause mortality and cancer progression or death among 1149 people in the Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group (SWOG) 80405 trial who completed a food frequency questionnaire at initiation of treatment for advanced or metastatic colorectal cancer. We examined saturated, monounsaturated, total and specific types (n‐3, long‐chain n‐3 and n‐6) of polyunsaturated fat, animal and vegetable fats. We hypothesized higher vegetable fat intake would be associated with lower risk of all‐cause mortality and cancer progression. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI). Over median follow‐up of 6.1 years (interquartile range [IQR]: 5.3, 7.2 y), we observed 974 deaths and 1077 events of progression or death. Participants had a median age of 59 y; 41% were female and 86% identified as White. Moderate or higher vegetable fat was associated with lower risk of mortality and cancer progression or death (HRs comparing second, third and fourth to first quartile for all‐cause mortality: 0.74 [0.62, 0.90]; 0.75 [0.61, 0.91]; 0.79 [0.63, 1.00];Ptrend: .12; for cancer progression or death: 0.74 [0.62, 0.89]; 0.78 [0.64, 0.95]; 0.71 [0.57, 0.88];Ptrend: .01). No other fat type was associated with all‐cause mortality and cancer progression or death. Moderate or higher vegetable fat intake may be associated with lower risk of cancer progression or death among people with metastatic colorectal cancer.
High prevalence of gram-negative and multiorganism surgical site infections after pediatric complex tethered spinal cord surgery: a multicenter study
Alexiades, Nikita G. , Shao, Belinda , Ahn, Edward S. , Blount, Jeffrey P. , Brockmeyer, Douglas L. , Hankinson, Todd C. , Sandberg, David I. , Heuer, Gregory G. , Feldstein, Neil A. , Anderson, Richard C. E. , Nesvick, Cody L. , Saiman, Lisa M.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | July 22, 2022 | Volume: 30 | Issue: 3 | Pages: 357-363

10.3171/2022.6.peds2238 | PMID 35901675 Get It

OBJECTIVE Complex tethered spinal cord (cTSC) release in children is often complicated by surgical site infection (SSI). Children undergoing this surgery share many similarities with patients undergoing correction for neuromuscular scoliosis, where high rates of gram-negative and polymicrobial infections have been reported. Similar organisms isolated from SSIs after cTSC release were recently demonstrated in a single-center pilot study. The purpose of this investigation was to determine if these findings are reproducible across a larger, multicenter study. METHODS A multicenter, retrospective chart review including 7 centers was conducted to identify all cases of SSI following cTSC release during a 10-year study period from 2007 to 2017. Demographic information along with specific microbial culture data and antibiotic sensitivities for each cultured organism were collected. RESULTS A total of 44 SSIs were identified from a total of 655 cases, with 78 individual organisms isolated. There was an overall SSI rate of 6.7%, with 43% polymicrobial and 66% containing at least one gram-negative organism. Half of SSIs included an organism that was resistant to cefazolin, whereas only 32% of SSIs were completely susceptible to cefazolin. CONCLUSIONS In this study, gram-negative and polymicrobial infections were responsible for the majority of SSIs following cTSC surgery, with approximately half resistant to cefazolin. Broader gram-negative antibiotic prophylaxis should be considered for this patient population.
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim, Ellen J. , Mangold, Aaron R. , DeSimone, Jennifer , Seminario‐Vidal, Lucia , Guitart, Joan , Appel, James, Lain, Edward , Korman, Neil J. , Zeitouni, Nathalie C., Nikbakht, Neda , Dawes, Kenneth, Akilov, Oleg E. , Carter, Joi, Kuzel, Timothy M. , Piette, Warren W., Bhatia, Neal , Musiek, Amy , Pariser, David M. , Elston, Dirk M. , Boh, Erin , Pacheco, Theresa , Zwerner, Jeffrey P., Bohjanen, Kimberly , Olsen, Elise A. , Wood, Gary S. , Rumage, Adam, Donini, Oreola , Haulenbeek, Andrea, Schaber, Christopher J. , Straube, Richard , Pullion, Christopher , Rook, Alain H. , Poligone, Brian , Mangold, A R , Akilov, Oleg E , Seminario-Vidal, L , Wong, Henry K. , Geskin, Larisa J. , Shinohara, Michi M. , Kim, Youn H , Duvic, Madeleine , Huen, Auris , Lee, Seung‐Tae , Girardi, Michael , Querfeld, Christiane

Mayo Clinic

JAMA Dermatology | July 20, 2022 | Volume: 158 | Issue: 9 | Pages: 1031

10.1001/jamadermatol.2022.2749 | PMID 35857290 Get It

Importance Given that mycosis fungoides−cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects. Topical synthetic hypericin ointment, 0.25%, activated with visible light is a novel, nonmutagenic photodynamic therapy (PDT). Objectives To determine the efficacy and safety of topical synthetic hypericin ointment, 0.25%, activated with visible light as a nonmutagenic PDT in early-stage MF/CTCL. Design, Settings, and Participants This was a multicenter, placebo-controlled, double-blinded, phase 3 randomized clinical trial (FLASH study) conducted from December 2015 to November 2020 at 39 academic and community-based US medical centers. Participants were adults (≥18 years) with early-stage (IA-IIA) MF/CTCL. Interventions In cycle 1, patients were randomized 2:1 to receive hypericin or placebo to 3 index lesions twice weekly for 6 weeks. In cycle 2, all patients received the active drug for 6 weeks to index lesions. In cycle 3 (optional), both index and additional lesions received active drug for 6 weeks. Main Outcomes and Measures The primary end point was index lesion response rate (ILRR), defined as 50% or greater improvement in modified Composite Assessment of Index Lesion Severity (mCAILS) score from baseline after 6 weeks of therapy for cycle 1. For cycles 2 and 3, open label response rates were secondary end points. Adverse events (AEs) were assessed at each treatment visit, after each cycle, and then monthly for 6 months. Data analyses were performed on December 21, 2020. Results The study population comprised 169 patients (mean [SD] age, 58.4 [16.0] years; 96 [57.8%] men; 120 [72.3%] White individuals) with early-stage MF/CTCL. After 6 weeks of treatment, hypericin PDT was more effective than placebo (cycle 1 ILRR, 16% vs 4%; P = .04). The ILRR increased to 40% in patients who received 2 cycles of hypericin PDT ( P < .001 vs cycle 1 hypericin) and to 49% after 3 cycles ( P < .001 vs cycle 1 hypericin). Significant clinical responses were observed in both patch and plaque type lesions and were similar regardless of age, sex, race, stage IA vs IB, time since diagnosis, and number of prior therapies. The most common treatment-related AEs were mild local skin (13.5%-17.3% across cycles 1-3 vs 10.5% for placebo in cycle 1) and application-site reactions (3.2%-6.9% across cycles 1-3 vs 4% for placebo in cycle 1). No drug-related serious AEs occurred. Conclusion and Relevance The findings of this randomized clinical trial indicate that synthetic hypericin PDT is effective in early-stage patch and plaque MF/CTCL and has a favorable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT02448381